{
  "ticker": "PAR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02962191",
  "id": "02962191",
  "pages": 7,
  "price_sensitive": true,
  "date": "20250626",
  "time": "0827",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250626/pdf/06l3tvmhglm9cz.pdf",
  "summary": "- **Acquisition Announcement**: Paradigm acquires Proteobioactives Pty Ltd, securing global patent rights for an oral PPS and COX-2 inhibitor combination therapy (Pentacoxib\u2122).  \n- **Strategic Rationale**: Expands Paradigm\u2019s osteoarthritis (OA) pipeline to early-stage and veterinary markets, complementing its injectable PPS phase 3 program.  \n- **Financial Terms**:  \n  - Upfront payment: **AUD $500,000** in cash.  \n  - Milestone payments: Up to **AUD $16M** tied to clinical/regulatory milestones (Phase 2, Phase 3, FDA approval, first commercial sale).  \n- **Key Data**: Pilot studies show pain reduction in hand/knee OA with the oral combination, enabling lower COX-2 inhibitor doses.  \n- **Market Potential**: Targets USD 11B+ COX-2 inhibitor market (human/veterinary), with near-term focus on veterinary development.  \n\n*No material information omitted; summary excludes non-material details like director quotes and background references.*",
  "usage": {
    "prompt_tokens": 4394,
    "completion_tokens": 221,
    "total_tokens": 4615,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-25T22:51:13.107326"
}